Mylan Hit With Patent Suit Over FazaClo ANDA

Law360, New York (July 26, 2010, 1:36 PM EDT) -- Cima Labs Inc. and Azur Pharma Ltd. have sued Mylan Inc. in an effort to prevent the generics maker from releasing its own version of schizophrenia drug FazaClo.

The complaint, filed Friday in the U.S. District Court for the District of Delaware, accuses Mylan of infringing two patents that cover an orally disintegrating tablet version of clozapine, sold under the brand name FazaClo.

Brooklyn Park, Minn.-based Cima holds the patents-in-suit and licenses them exclusively to Azur, based in Dublin, Ireland.

The validity of the patents, both...
To view the full article, register now.